Pere Barba

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Michael R. Bishop, Michael Dickinson, Duncan Purtill et al. · New England Journal of Medicine · 2021 · 491 citations · Full text

Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

Josep‐María Ribera, Albert Oriol, Mireia Morgades et al. · Journal of Clinical Oncology · 2014 · 251 citations · Full text

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F. Dagnew, Osman İlhan, Won Sik Lee et al. · The Lancet Infectious Diseases · 2019 · 242 citations

Vaccination, Vaccine Safety, Vaccinology +11

Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial

Manuela Aguilar‐Guisado, Ildefonso Espigado, Almudena Martín‐Peña et al. · The Lancet Haematology · 2017 · 230 citations

Antibiotics, Antimicrobial Stewardship, Phase 4 +9

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni et al. · Journal for ImmunoTherapy of Cancer · 2022 · 169 citations · Full text